Monoclonal Patents (Class 530/388.1)
Human (Class 530/388.15)
Binds microorganism or normal or mutant component or product thereof (e.g., animal cell, cell-surface antigen, secretory product, etc.) (Class 530/388.2)
Binds drug, hapten, hapten--carrier complex, or specifically-identified chemical structure (e.g., theophylline, digoxin, etc.) (Class 530/388.9)
  • Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
    Patent number: 9028826
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Dartmouth College
    Inventor: Randolph J. Noelle
  • Anti-phospho-Akt antibodies
    Patent number: 9029512
    Abstract: The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 12, 2015
    Assignee: Nuclea Biotechnologies, Inc.
    Inventor: Patrick J. Muraca
  • Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
    Patent number: 9028833
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: May 12, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Anti-PCSK9 antibodies with pH dependent antigen binding
    Patent number: 9029515
    Abstract: The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: May 12, 2015
    Assignees: Rinat Neuroscience Corp., Pfizer Inc.
    Inventors: Jaume Pons, Jeffrey Raymond Chabot, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Hong Liang, Kapil Mayawala, Jerome Thomas Mettetal, II, Arvind Rajpal, David Louis Shelton
  • Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
    Patent number: 9028816
    Abstract: The present invention relates to polypeptides and polypeptide constructs comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: May 12, 2015
    Assignee: Ablynx N.V.
    Inventor: Karen Silence
  • Dual variable domain immunoglobulins and uses thereof
    Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • USE OF CHARGED FLUOROCARBON COMPOSITIONS IN METHODS FOR PURIFICATION OF BIOMOLECULES
    Publication number: 20150125929
    Abstract: The present invention relates to novel and improved methods for the purification of biomolecules. In particular, the present invention relates to methods of protein purification which employ a porous solid support modified with a charged fluorocarbon composition.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 7, 2015
    Inventors: Mikhail Kozlov, Wilson Moya, Jad Jaber, William Cataldo, Ajish Potty, Christopher Gillespie
  • Anti-(+)—methamphetamine monoclonal antibodies
    Patent number: 9023353
    Abstract: The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 5, 2015
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Samuel Michael Owens, Ralph Henry, Alicia Brown
  • Antibodies that bind to IL-23
    Patent number: 9023358
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: May 5, 2015
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Anti-CD27 antibody
    Patent number: 9023999
    Abstract: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 5, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Katsuhiro Mori, Naoko Hiura, Tsuguo Kubota, Akiko Furuya, Yutaka Kanda, Mitsuo Satoh
  • MeCP2 ISOFORM-SPECIFIC ANTIBODY FOR DETECTION OF ENDOGENOUS EXPRESSION OF MeCP2E1
    Publication number: 20150118235
    Abstract: An antibody that binds a MeCP2E1 isoform of MeCP2 protein, wherein the antibody comprises a region comprising the amino acid sequence of SEQ ID NO:4. A method for detecting and/or monitoring a disease or a disorder caused by an over-expression or an under-expression of a MeCP2E1 isoform of MeCP2 protein, comprising the steps of: (i) obtaining a first sample from a mammalian subject; (ii) contacting the first sample with the anti-MeCP2E1antibody; (iii) removing unbound antibody from the sample; (iv) conducting an immunoassay on the first sample to determine a first value for expression of the MeCP2E1 isoform; (v) comparing the first value to a reference value for expression of the MeCP2E1 isoform in healthy mammalian subjects; wherein a deviation of the first value from the reference value indicates the presence of a disease or a disorder caused by an over-expression or an under-expression of the MeCP2E1 isoform.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 30, 2015
    Applicant: University of Manitoba
    Inventor: Mojgan Rastegar
  • Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis
    Publication number: 20150118230
    Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
    Type: Application
    Filed: February 15, 2013
    Publication date: April 30, 2015
    Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
  • Prostasin partial peptide and anti-prostasin antibody
    Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Multispecific antibodies
    Patent number: 9017686
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Jenny M. Bostrom, Germaine Fuh
  • DC-STAMP antibodies
    Patent number: 9018358
    Abstract: Provided herein are antibodies that specifically bind an epitope of DC-STAMP. Specifically, provided herein are monoclonal antibodies that bind an epitope of DC-STAMP, wherein the epitope comprises the amino acid sequence Glu-Val-His-Leu-Lys-Leu-His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:1). Optionally, the epitope comprises the amino acid sequence His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:2). Optionally, the epitope comprises the amino acid sequence Lys-Gln-Gly-Thr-Gln (SEQ ID NO:3).
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: April 28, 2015
    Assignee: University of Rochester
    Inventors: Edward M. Schwarz, Kofi A. Mensah, Yahui Grace Chiu, Christopher T. Ritchlin
  • Anti-VEGF antibodies
    Patent number: 9018357
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Antibodies specific for sclerostin and methods for increasing bone mineralization
    Patent number: 9011856
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 21, 2015
    Assignee: UCB Pharma S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Diagnostic kit for IGFBP-4 proteolytic fragments in a patient sample
    Patent number: 9012610
    Abstract: The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: April 21, 2015
    Assignee: Hytest Ltd.
    Inventors: Alexey G. Katrukha, Alexander B. Postnikov, Tatiana I. Solovyeva, Alexey V. Kharitonov
  • Anti-DLL3 antibody drug conjugates and methods of use
    Patent number: 9011854
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: April 21, 2015
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Variable region sequences of IL-31 monoclonal antibodies and methods of use
    Patent number: 9011858
    Abstract: Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: April 21, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine M. Bilsborough, Shirley A. Rene
  • Methods for treatment of inflammatory diseases
    Patent number: 9005615
    Abstract: The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment epithelium-derived factor (PEDF) and methods of screening for agents that inhibit PEDF.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: April 14, 2015
    Assignee: The Feinstein Institute For Medical Research
    Inventors: Kevin Tracey, Sangeeta Chavan
  • Antikine antibodies that bind to multiple CC chemokines
    Patent number: 9005617
    Abstract: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1?/CCL3, MIP-1?/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: April 14, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Dan Allison, Carol Raport
  • Modulators of ACYL-COA Lysocardiolipin Acyltransferase 1 (ALCAT1) and Uses Thereof
    Publication number: 20150098938
    Abstract: Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided.
    Type: Application
    Filed: February 15, 2013
    Publication date: April 9, 2015
    Applicant: The Penn State Research Foundation
    Inventor: Yuguang Shi
  • Immunobinders directed against sclerostin
    Patent number: 8999331
    Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: April 7, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yuliya Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
  • Lipoprotein-associated phospholipase A2 antibody compositions and methods of use
    Patent number: 9000132
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: April 7, 2015
    Assignee: diaDexus, Inc.
    Inventors: Paul Levi Miller, Laura Corral
  • Antibodies that neutralize botulinum neurotoxins
    Patent number: 9000131
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 7, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren
  • Methods for treating chronic obstructive pulmonary disease
    Patent number: 8999339
    Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 7, 2015
    Inventor: Clifford G. Risk
  • Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
    Patent number: 8999936
    Abstract: The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A? 42/40 protofibril comprising N-terminal truncated A? forms and (ii) A? 42/40 Arc protofibril comprising N-terminal truncated A? forms and (b) has no or little cross-reactivity to A? 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: April 7, 2015
    Assignee: BioArctic Neuroscience AB
    Inventors: Pär Gellerfors, Lars Lannfelt
  • Antibodies to OX-2/CD200 and uses thereof
    Patent number: 9000133
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: April 7, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • METHOD FOR CHROMATOGRAPHY REUSE
    Publication number: 20150093800
    Abstract: The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products.
    Type: Application
    Filed: September 5, 2014
    Publication date: April 2, 2015
    Inventors: Ekta MAHAJAN, Kapil KOTHARY, Joanna SO, Jay WERBER
  • Antagonist antibodies against GDF-8 and uses therefor
    Patent number: 8992913
    Abstract: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: March 31, 2015
    Assignee: Pfizer Inc.
    Inventors: Michelle M. Mader, James R. Apgar, Kevin D. Parris
  • Antibodies for the detection of integrin complexes in FFPE material
    Patent number: 8993261
    Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 31, 2015
    Assignee: Merck Patent GmbH
    Inventors: Simon Goodman, Claudia Wilm, Francesc Mitjans
  • Antibodies specific for sclerostin and methods for increasing bone mineralization
    Patent number: 8992911
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: March 31, 2015
    Assignee: UCB Pharma S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Anti-IL-6 antibodies for the treatment of arthritis
    Patent number: 8992920
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventor: Jeffrey T. L. Smith
  • ANTI-CD22 ANTIBODIES
    Publication number: 20150086562
    Abstract: Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof including therapeutic compositions, methods and devices.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 26, 2015
    Inventors: Jay Short, Gerhard Frey, Hwai Wen Chang, William Boyle
  • BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20150086552
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 26, 2015
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty, Milan Gao, Steven Sheriff, Noah Ditto, Nels B. Hamacher
  • ANTI-VEGF ANTIBODIES
    Publication number: 20150086568
    Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
    Type: Application
    Filed: November 20, 2014
    Publication date: March 26, 2015
    Applicant: GENENTECH, INC.
    Inventors: Germaine FUH, Chingwei V. LEE
  • Dual specific binding proteins directed against IL-1? and/or IL-17
    Patent number: 8987418
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: March 24, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
  • DNA encoding function modifying Na1.7 antibodies
    Patent number: 8986954
    Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: March 24, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
  • Stabilized liquid anti-RSV antibody formulations
    Patent number: 8986686
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 24, 2015
    Assignee: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Compositions and methods for increasing bone mineralization
    Patent number: 8986685
    Abstract: Described herein are pharmaceutical compositions comprising an anti-sclerostin antibody and an inhibitor of bone resorption.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: March 24, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Mary E. Brunkow, David J. Galas, Brian Kovacevich, John T. Mulligan, Bryan W. Paeper, Jeffrey Van Ness, David G. Winkler
  • Nucleic acid encoding DLL3 antibodies
    Patent number: 8986972
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 24, 2015
    Assignee: Stem CentRx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Amyloid-beta binding proteins
    Patent number: 8987419
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 24, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Lorenzo Benatuil
  • TREATMENT OF ACUTE INFLAMMATION IN THE RESPIRATORY TRACT
    Publication number: 20150079105
    Abstract: This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of acute inflammation of the respiratory tract, especially acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Levels of CCL7 have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of CCL7 and/or other members of the PAR1-CCL7 axis, or CCL2 can be used to prevent and/or treat these conditions.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Applicant: ucl Business PLC
    Inventors: Rachel Chambers, Paul Mercer, Andrew Williams
  • Anti-RANTES Antibodies
    Publication number: 20150079099
    Abstract: The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
    Type: Application
    Filed: March 18, 2014
    Publication date: March 19, 2015
    Inventors: Nicolas Fischer, Marie Kosco-Vilbois, François Mach
  • B7-H1 Antibodies
    Patent number: 8981063
    Abstract: The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: March 17, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Lieping Chen
  • Monoclonal antibody that binds human notch2 and notch3
    Patent number: 8980260
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 17, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 8981064
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: March 17, 2015
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Bei Shan, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Antibody being capable of binding to transforming growth factor alpha and having growth-suppressing activity on cancers having Ras gene mutation
    Patent number: 8980257
    Abstract: It has been found out that among antibodies showing reactivity with wild type TGF-?, antibodies less reactive with G79A-substituted TGF-? have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: March 17, 2015
    Assignee: Medical & Biological Laboratories Co., Ltd.
    Inventors: Makoto Kaneda, Yoshihiro Fujii, Yoshihiro Hayata, Yoshiro Kishi, Ichiro Yahara
  • Antibody targeting osteoclast-associated protein
    Patent number: 8980272
    Abstract: The present invention relates to a method of detecting metabolic bone disorders using a gene expressed at a high level in osteoclasts, a method of screening for a compound effective for treatment and/or prevention of metabolic bone disorders, and a pharmaceutical composition for treatment and/or prevention of metabolic bone disorders. Specifically, the present invention relates to a method of detecting metabolic bone disorders using expression of the human DC-STAMP gene as an indicator, a pharmaceutical composition containing an antibody which is capable of specifically recognizing human DC-STAMP and suppressing formation of osteoclasts, and so forth.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: March 17, 2015
    Assignee: Sankyo Company, Limited
    Inventors: Hisayuki Nomiyama, Toshio Kukita, Yoshiharu Hiruma